ClinicalTrials.gg
CompletedNCT05610189Updated Feb 8, 2024

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

A Phase 1 interventional study of Tavapadon in Parkinson Disease, sponsored by Cerevel Therapeutics, LLC. Completed at 6 sites in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
8th of 11
25 · median 57
Started
2022
with 1 other
Phase 1
5 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
3 of 11
Cerevel Therapeutics, LLC

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 11th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
  • Dopamine Agonist
  • Dopamine Therapy
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. of 17.5 to 38.0 kilograms per square meter (kg/m\^2), inclusive, and total body weight >50 kg (110 pounds [lb]) at Screening.
  2. Participants with a diagnosis of Parkinson's disease (PD) that is consistent with the United Kingdom (UK) Parkinson's Disease Society Brain Bank diagnostic criteria.
  3. Must be modified Hoehn \& Yahr Stage I-III inclusive.
  4. Must be on a stable dose of L-Dopa of at least 300 mg daily in conjunction with a dopa-decarboxylase inhibitor (e.g., L-Dopa/carbidopa, L Dopa/carbidopa/entacapone or L-Dopa/benserazide) administered at least 3 times per day for at least 2 weeks prior to the Day 1 Visit.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or poststroke parkinsonism).
  2. Participants with a history of psychosis or hallucinations within the previous 12 months.
  3. Participants with epilepsy, or history of epilepsy, or conditions that lower seizure threshold, seizures of any etiology (including substance or drug withdrawal), or who have increased risk of seizures as evidenced by history of electroencephalogram with epileptiform activity are excluded. Participants with a history of febrile seizures only are allowed with medical monitor approval.
  4. History of substance or alcohol-use disorder (excluding nicotine; , 5th edition criteria) within 2 years prior to signing the form (ICF).
  5. Participants who answer "Yes" on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Participants who answer "Yes" on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months OR Participants who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
  6. Participants who have attempted suicide in the past.
  7. Positive result for (HIV) antibody, surface antigen, hepatitis B core antibody, or antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
  8. Have been diagnosed with symptomatic coronavirus disease (COVID-19) or test positive (i.e., using polymerase chain reaction [PCR] or rapid antigen test) for COVID-19 within 30 days prior to signing the ICF.
  9. Participants taking strong or moderate cytochrome P450 family 3 subfamily A member 4 () inducers or inhibitors or who would be likely to require concomitant therapy with CYP3A4 inducers or inhibitors during the trial.

NOTE: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg

    Participants will receive tavapadon 1x15 mg tablet, orally, once daily (QD) from Day 15 to 21. Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 22 to 28.

    Drug: Tavapadon

  • Experimental
    Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg

    Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 15 to 21. Participants will receive tavapadon 1x15 mg tablet, orally, QD from Day 22 to 28.

    Drug: Tavapadon

Interventions

  • Oral tablets

    Also known as: CVL-751, PF-06649751

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  2. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

Secondary outcomes

  1. Minimum Steady-state Plasma Concentration (Cmin,ss) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  2. Average Steady-state Plasma Concentration (Cavg,ss) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  3. Trough Concentration (Ctrough) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  4. Time of Maximum Observed Concentration (Tmax) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  5. Degree of Fluctuation [(Cmax - Cmin)/Cavg,ss] of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  6. Peak-to-Trough Ratio (PTR) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  7. Swing [(Cmax - Cmin)/Cmin,ss] of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  8. Apparent Clearance of Tavapadon From Plasma (CL/F)

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 28

  9. Number of Participants With Adverse Events (AEs) and AEs by Severity

    Time frame: Up to Day 36

  10. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values

    Time frame: Up to Day 29

  11. Number of Participants With Clinically Significant Changes in Vital Sign Values

    Time frame: Up to Day 29

  12. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Time frame: Up to Day 29

  13. Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results

    Time frame: Up to Day 29

  14. Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Up to Day 29

07

Study locations

6 sites
  • Los Alamitos, California
    Los Alamitos, California 90720, United States
  • Hollywood, Florida
    Hollywood, Florida 33024, United States
  • Orlando, Florida
    Orlando, Florida 32806, United States
  • South Miami, Florida
    South Miami, Florida 33143, United States
  • Decatur, Georgia
    Decatur, Georgia 30030, United States
  • Farmington Hills, Michigan
    Farmington Hills, Michigan 48334, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2023, 11 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 11 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 9, 2022
StartActual
Dec 15, 2022
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 17, 2023
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610189
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Dec 15, 2022
Primary completion
Dec 12, 2023
Completion
Dec 17, 2023
Last update
Feb 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion